Damora Therapeutics, Inc. annual report, FY2022

Business Context and Reporting Period

The submitted filing identifies the registrant as Galecto, Inc., not Damora Therapeutics, Inc. It is a Form 10-K for the fiscal year ended December 31, 2022, filed March 9, 2023. Galecto is a clinical-stage biotechnology company developing small-molecule inhibitors of galectin-3 and LOXL2 for fibrotic diseases and cancer. Its principal candidates are GB0139, GB1211 and GB2064.

All programs remained investigational; the company had no products approved for commercial sale and generated no product revenue.

Key Financial Metrics

Metric20222021Change
Revenue$0$0No change
Research and development expense$48.2 million$38.5 millionUp 25%
General and administrative expense$13.0 million$13.7 millionDown 5%
Total operating expenses$61.2 million$52.2 millionUp 17%
Loss from operations$(61.2) million$(52.2) millionLoss increased 17%
Net loss$(61.6) million$(51.8) millionLoss increased 19%
Basic and diluted loss per share$(2.43)$(2.05)Loss per share increased
Net cash used in operating activities$(42.9) million$(52.3) millionUse decreased $9.4 million
Cash, cash equivalents and marketable securities$66.1 million$109.2 millionDown $43.1 million
Accumulated deficit$217.7 million$156.1 millionIncreased $61.6 million

At December 31, 2022, cash and cash equivalents were $32.8 million and marketable securities totaled $33.3 million, including $27.4 million current and $5.8 million non-current. Total assets were $73.2 million, total liabilities were $11.4 million, and stockholders’ equity was $61.8 million.

The filing does not disclose conventional profitability or operating margins because the company had no revenue. No borrowings or funded debt are disclosed; liabilities primarily consisted of accounts payable, accrued expenses and operating lease liabilities.

Material Changes Versus the Prior Comparable Period

  • Research and development expense increased by $9.7 million, primarily due to higher clinical-trial activity, additional personnel and other development costs. Clinical trial-related expense increased by approximately $9.1 million.
  • General and administrative expense declined by $0.7 million, largely because of lower consulting and legal costs, partly offset by higher personnel and stock-based compensation costs.
  • Net loss increased by $9.9 million to $61.6 million. Other income of $0.5 million in 2021 became other expense of $0.4 million in 2022, primarily because of foreign-exchange losses.
  • Operating cash usage improved from $52.3 million to $42.9 million, while cash and marketable securities declined from $109.2 million to $66.1 million.
  • The company sold 390,560 shares through its at-the-market program during 2022, generating $0.5 million of net proceeds. Shares outstanding increased from 25.26 million at year-end 2021 to 25.65 million at year-end 2022.
  • Stock-based compensation increased from $4.5 million to $5.6 million. Outstanding stock options increased to 5.8 million at year-end 2022.

Clinical Progress, Outlook and Unusual Items

  • GB0139: The Phase 2b GALACTIC-1 trial in idiopathic pulmonary fibrosis completed enrollment of 144 patients under an amended protocol. The company expected topline results in mid-2023. Earlier, a data safety monitoring board identified an imbalance in serious adverse events and dosing was discontinued for the 10 mg arm and for patients receiving background nintedanib or pirfenidone; the trial continued with the 3 mg dose or placebo.
  • GB2064: In the Phase 2a MYLOX-1 trial for myelofibrosis, four of five evaluable patients who completed at least six months of monotherapy experienced at least a one-grade reduction in bone-marrow collagen fibrosis. Sixteen patients had been dosed at the intermediate assessment, with eight continuing or completing treatment and eight discontinuing due to adverse events or disease progression. Topline results were expected by the end of 2023.
  • GB1211 in liver cirrhosis: The Phase 1b/2a GULLIVER-2 trial reported statistically significant reductions in ALT, AST and GGT after 12 weeks, along with reductions in galectin-3 and CK-18. The trial enrolled 15 GB1211 patients and 15 placebo patients. The company stated that serious adverse events in one GB1211 patient were consistent with severe liver disease and deemed unrelated to treatment.
  • GB1211 in oncology: The GALLANT-1 trial combined GB1211 with Roche’s atezolizumab in first-line non-small-cell lung cancer. Two serious autoimmune-type skin rashes occurred among the first six patients receiving 200 mg twice daily; investigators attributed them to atezolizumab, and the protocol dose of GB1211 was reduced to 100 mg twice daily for the next cohort. Interim safety data were expected in the second quarter of 2023 and topline Part B results in the first half of 2024.
  • In October 2022, Galecto entered an agreement with Providence Portland Medical Center’s Earle A. Chiles Research Institute for a planned Phase 2 investigator-initiated trial of GB1211 with pembrolizumab in metastatic melanoma and head and neck squamous cell carcinoma. The trial was expected to begin in the second half of 2023.
  • Management estimated that the $66.1 million of cash, cash equivalents and marketable securities at December 31, 2022 would fund operations into the second half of 2024. The estimate is subject to substantial uncertainty, and additional capital will be required to complete clinical development.
  • There were no material legal proceedings reported. Management stated that disclosure controls and internal control over financial reporting were effective as of December 31, 2022. The independent auditor audited the financial statements but was not engaged to provide an opinion on internal control effectiveness.

Principal Risks and Contingencies

  • Continued significant losses, negative operating cash flow and dependence on additional equity, debt, licensing or collaboration financing.
  • High clinical and regulatory risk: none of the product candidates has demonstrated successful late-stage development or obtained marketing approval.
  • Safety concerns, including the prior serious-adverse-event imbalance in GALACTIC-1 and serious skin reactions in GALLANT-1.
  • Patient enrollment, trial execution, third-party contract research, manufacturing and supply-chain risks, including effects from COVID-19, geopolitical instability and the Russia-Ukraine conflict.
  • Potential dilution from future equity offerings and possible loss of Nasdaq listing if the common stock fails to meet minimum requirements.
  • Competition from larger biotechnology and pharmaceutical companies with greater financial and commercial resources.
  • Intellectual-property validity, enforcement and freedom-to-operate risks, as well as data privacy, healthcare regulation and reimbursement risks.

Investor Verification Checklist

  • Verify the issuer identity: the provided filing is for Galecto, Inc. (Nasdaq: GLTO), not Damora Therapeutics, Inc.
  • Reconcile the reported $66.1 million liquidity balance with the company’s expected operating runway and subsequent financing activity.
  • Review the full audited financial statements and notes for cash restrictions, marketable-security composition, lease obligations, tax-credit realizability and any later events.
  • Assess the full GALACTIC-1 safety and efficacy results, including the effect of the discontinued dose groups and combination-treatment arms.
  • Validate the small-sample GB2064 and GB1211 findings in larger, controlled studies and distinguish biomarker changes from demonstrated clinical benefit.
  • Monitor future capital raises, dilution, Nasdaq compliance and the company’s ability to fund all three clinical programs.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.